Abstract 240P
Background
This study aimed to investigate the role of the serpin peptidase inhibitor, clade E, member 2 (SERPINE2), in patients with oral squamous cell carcinoma (OSCC).
Methods
We investigated SERPINE2 mRNA expression in cases of squamous cell carcinoma from online databases, explored the relationship between SERPINE2 and clinicopathological characteristics and prognosis in OSCC patients, and determined the potential of SERPINE2 to affect OSCC proliferation, migration and invasion capability in vitro.
Results
The expressions of SERPINE2 were higher in tumor tissues than that in normal tissues in TNMplot. High mRNA expression of SERPINE2 was significantly correlated with poor overall 5-year survival in KmPlot. High SERPINE2 immunoexpression was significantly correlated with adverse pathologic parameters. High SERPINE2 immunoexpression was significantly associated with worse overall survival. SERPINE2 promotes cell proliferation, cell migration, and invasion ability in OSCC cell lines. Table: 240P
Relationships between the immunoscore of SERPINE2 and clinicopathological parameters in 122 patients
Parameters | No. | Mean ± SEM | Median | p | |
Agea | |||||
≤ 54 | 73 | 147.47 ± 7.77 | 160 | 0.132 | |
> 54 | 49 | 163.83 ± 8.86 | 165 | ||
Gendera | |||||
Male | 107 | 152.59 ± 6.45 | 160 | 0.561 | |
Female | 15 | 164.33 ± 13.21 | 160 | ||
Tumor siteb | |||||
Buccal | 77 | 152.08 ± 7.29 | 160 | 0.700 | |
Retromolar | 24 | 148.96 ± 13.50 | 165 | ||
Tongue | 7 | 170.36 ± 25.33 | 170 | ||
Others | 14 | 165.36 ± 19.25 | 171 | ||
Histological gradeb | |||||
Well | 45 | 149.00 ± 8.18 | 165 | 0.720 | |
Moderate | 71 | 156.13 ± 8.35 | 160 | ||
Poor | 6 | 167.08 ± 30.81 | 183 | ||
Stagea | |||||
I–II | 66 | 133.60 ± 7.41 | 153 | <0.001* | |
III–IV | 56 | 178.13 ± 8.34 | 184 | ||
Tumor statusa | |||||
T1–2 | 78 | 139.20 ± 7.18 | 160 | <0.001* | |
T3–4 | 44 | 180.34 ± 8.98 | 186 | ||
Nodal metastasisa | |||||
Absent | 91 | 145.36 ± 6.39 | 160 | 0.011* | |
Present | 31 | 179.52 ± 12.64 | 180 | ||
Distant metastasisa | |||||
Absent | 107 | 148.69 ± 6.36 | 160 | 0.010* | |
Present | 15 | 192.17 ± 11.12 | 188 |
ap-value by Mann–Whitney U testbp-value by Kruskal–Wallis test. *Significance at p < 0.05
Conclusions
Our results suggest that SERPINE2 may serve as a prognostic biomarker, associated with the tumorigenesis and aggressiveness of OSCC, and a potential therapeutic target in oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This research was supported by a grant from Kaohsiung Veterans General Hospital (grant number VGHKS109-074) in Taiwan, ROC.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract